The consistent symptom-modifying effect across trials strongly implies that -3 PUFAs are a viable dietary strategy for managing OA-related pain, particularly for individuals seeking or requiring adjunctive approaches to pharmacotherapy
Se consultaron artculos indexados en PubMed de ensayos clnicos, metaanlisis, cartas al editor, documentos regulatorios internaciones y reportes de farmacovigilancia relacionados con el uso de ArGLP-1, especialmente semaglutida, liraglutida y dulaglutida
Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere
The genetics part influences behaviour around food, such as hunger, satiety, and food reward, says Dr
Inflammaging and oxidative stress in human diseases: from molecular mechanisms to novel treatments